Shares of BioDelivery Sciences International Inc. (NASDAQ:BDSI) saw unusually-high trading volume on Thursday . Approximately 935,115 shares changed hands during mid-day trading, an increase of 43% from the previous session’s volume of 651,966 shares.The stock last traded at $2.69 and had previously closed at $2.46.

BDSI has been the topic of a number of research analyst reports. FBR & Co restated a “buy” rating on shares of BioDelivery Sciences International in a research note on Thursday, May 12th. Piper Jaffray Cos. restated an “overweight” rating and issued a $4.00 target price (down from $6.00) on shares of BioDelivery Sciences International in a research note on Thursday, May 12th. Cantor Fitzgerald lowered BioDelivery Sciences International from a “buy” rating to a “hold” rating and decreased their target price for the stock from $9.00 to $5.00 in a research note on Wednesday, May 11th. Zacks Investment Research lowered BioDelivery Sciences International from a “buy” rating to a “hold” rating in a research note on Wednesday, July 27th. Finally, Janney Montgomery Scott restated a “hold” rating and issued a $4.00 target price on shares of BioDelivery Sciences International in a research note on Tuesday, July 12th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company. BioDelivery Sciences International presently has a consensus rating of “Hold” and a consensus target price of $8.25.

The stock has a 50-day moving average of $2.45 and a 200-day moving average of $2.99. The company’s market cap is $142.02 million.

BioDelivery Sciences International (NASDAQ:BDSI) last released its earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported ($0.31) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.31). The company had revenue of $5 million for the quarter, compared to analysts’ expectations of $3.35 million. During the same quarter last year, the firm posted ($0.37) earnings per share. BioDelivery Sciences International’s revenue for the quarter was up 194.1% on a year-over-year basis. Equities research analysts predict that BioDelivery Sciences International Inc. will post ($1.16) earnings per share for the current year.

An institutional investor recently raised its position in BioDelivery Sciences International stock. Bank of Montreal Can increased its stake in shares of BioDelivery Sciences International Inc. (NASDAQ:BDSI) by 3.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 829,056 shares of the specialty pharmaceutical company’s stock after buying an additional 28,838 shares during the period. Bank of Montreal Can owned about 1.57% of BioDelivery Sciences International worth $3,971,000 at the end of the most recent reporting period.

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.